Bernstein Research Conference: 3 soluciones 3 a "una piedra en el camino" ( caducidad de patentes).

Bernstein Research organizó conferencia para analizar alternativas a la "piedra en el camino" que representa para las Big Pharma la caducidad inminente (próximos cinco años) de patentes de 18 de los 20 más importantes (actuales) "blockbusters".

Son tres según el analista de Bernstein Tim Anderson, MD:


1) DIVERSIFICACIÓN

"Diversification is one strategy companies have pursued to address the R&D productivity problem. Adding new business lines can help decrease dependence on branded prescription drugs, or so the thinking goes.

But let's be realistic, said Anderson. It took Johnson & Johnson, Abbott Laboratories and Novartis years to become the well-diversified businesses they are. “Diversification is easy to talk about, but actually achieving diversification effectively is another matter,” he commented in a research note summarizing the conference." (...)

2) M&A

As revenue from high-margin products dries up, instead of trimming R&D, companies can use their balance sheets to “buy” P&L. This is what Pfizer did with its $68-billion purchase of Wyeth last year.(...)

3) GESTIÓN DE COSTOS

...much of the low-hanging fruit has been picked. But consensus among executives at the conference was that there is still “substantially more” cost-cutting potential. A consultant (the conference included speakers from McKinsey & Co. and ZSAssociates) noted that only two or three companies are exploiting “differential resourcing,” which refers to tailoring sales force intensity by small geographic regions (vs. taking a one-size fits all approach).(...)

Ver